Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 101; no. 8; pp. e339 - e342
Main Authors de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.08.2016
Subjects
Antibodies, Monoclonal - therapeutic use
Antibody-Dependent Cell Cytotoxicity - drug effects
Bone Marrow Cells - physiology
Cell Line, Tumor
Drug Resistance, Neoplasm - drug effects
Drug Synergism
Humans
Imidazoles - pharmacology
Imidazoles - therapeutic use
Immunotherapy - methods
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Naphthoquinones - pharmacology
Naphthoquinones - therapeutic use
Online Only
Stromal Cells
T-Lymphocytes, Cytotoxic - drug effects
T-Lymphocytes, Cytotoxic - immunology
multiple myeloma
sepantronium bromide
bone marrow stromal cell
abrogation
cell lysis
deratumumab
Online AccessGet full text

Cover

More Information
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2015.139667